Bardoxolone
Catalog No.
A3220
Once-a-day treatment for CKD
Featured Products
Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are potent inducers of the transcription factor Nrf2, an important biological target that controls the production of many of the body's antioxidant and detoxification enzymes. Because oxidative stress and inflammation occur throughout the course of chronic kidney disease (CKD) and are known to contribute to loss of kidney function, agents that activate the Nrf2 pathway in patients with CKD may provide a novel method for preserving or improving kidney function. Bardoxolone methyl is currently being investigated as a potential oral once-a-day treatment for CKD.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 491.66 |
| Cas No. | 218600-44-3 |
| Formula | C31H41NO4 |
| Synonyms | CDDO;RTA 401;RTA401;RTA-401 |
| Solubility | ≥49.2 mg/mL in DMSO; insoluble in H2O; ≥2.682 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid |
| SDF | Download SDF |
| Canonical SMILES | CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)O)C |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
